1. Basic Product Identification
Alectinib
INN Name: Alectinib
Brand Name: Alecensa®
Therapeutic Class: Targeted anticancer therapy
Pharmacological Class: ALK (Anaplastic Lymphoma Kinase) inhibitor
Dosage Form: Oral capsules
Primary Indication: ALK-positive non-small cell lung cancer (NSCLC)
2. Therapeutic Knowledge
Alectinib is used in:
First-line treatment of ALK-positive NSCLC
Treatment of metastatic lung cancer with ALK rearrangements
CNS metastases (brain penetration is a key advantage)
???? Clinical advantages:
Superior progression-free survival vs crizotinib
Strong CNS activity (crosses blood–brain barrier)
Better tolerability profile
3. Mechanism of Action (MOA)
Alectinib is a highly selective ALK tyrosine kinase inhibitor (TKI).
Mechanism:
Inhibits ALK phosphorylation
Blocks downstream signaling pathways:
PI3K/AKT
MAPK pathway
???? Result:
Inhibition of tumor cell proliferation
Induction of apoptosis in ALK-driven cancer cells
Also inhibits:
RET kinase (minor off-target activity)
4. Pharmacokinetics (ADME)
Absorption: High oral absorption with food
Bioavailability: Improved with fat-containing meals
Tmax: ~4–6 hours
Protein binding: >99%
Metabolism: Hepatic (CYP3A4 → active metabolite M4)
Half-life:
Alectinib: ~32 hours
Metabolite M4: similar activity
Excretion: Fecal (~98%), minimal renal
⚠️ CYP3A interactions are clinically relevant
5. Dosage & Administration
Standard dose: 600 mg orally twice daily
Taken with food
Dose adjustment:
Liver impairment
Drug interactions (CYP3A inhibitors/inducers)
Monitoring:
Liver function tests
CPK levels (myopathy risk)
Lung function (pneumonitis risk)
6. Formulation Knowledge
Hard gelatin capsules
High-dose oral solid formulation
Challenges:
Low aqueous solubility
High lipophilicity
Food-dependent absorption
Excipients:
Lactose monohydrate
Microcrystalline cellulose
Sodium starch glycolate
Magnesium stearate
Capsule shell gelatin
7. Raw Materials Knowledge
API: Alectinib hydrochloride
Synthetic class:
Small molecule kinase inhibitor
Key intermediates:
Aromatic heterocycles
Benzamide derivatives
Critical raw material concerns:
Chirality control (if applicable in intermediates)
Polymorphic form consistency
High potency handling controls
8. Manufacturing Process Knowledge
API synthesis:
Multi-step organic synthesis
Heterocyclic ring formation
Final salt formation (HCl salt)
Purification via crystallization & chromatography
Capsule manufacturing:
Micronization (improves dissolution)
Blending with lubricants
Capsule filling under humidity control
Critical process controls:
Particle size distribution
Polymorph control
Content uniformity (high-dose oncology drug)
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay (potency)
Related substances (impurity profiling)
Dissolution testing (critical for bioavailability)
Residual solvents (GC)
Polymorph identification (XRPD)
Content uniformity
Stability-indicating methods
Critical quality attributes (CQAs):
Dissolution rate
Impurity thresholds
Crystal form stability
10. Regulatory Knowledge
Approved globally for ALK-positive NSCLC
Classified as:
Targeted oncology therapy (TKI)
Regulatory requirements:
Companion diagnostic (ALK testing mandatory)
Oncology risk management plan
CNS efficacy data requirement
11. Storage & Stability
Store at 20–25°C
Protect from:
Moisture
Excess heat
Stable polymorphic form must be maintained
Stability risks:
Polymorphic conversion
Degradation under humidity
Photostability generally stable but still controlled
12. Packaging Knowledge
HDPE bottles with desiccant
Blister packs (Alu-Alu for moisture protection)
Child-resistant oncology packaging
Secondary packaging:
Oncology hazard labeling
Storage instructions (dry place critical)
13. Safety & Toxicology
Major adverse effects:
Hepatotoxicity (ALT/AST elevation)
Myalgia and CPK elevation
Constipation
Interstitial lung disease (rare but serious)
Bradycardia
Contraindications:
Severe liver impairment (dose adjustment required)
Monitoring:
Liver function
CPK
Pulmonary symptoms
14. Market & Commercial Knowledge
Competes with:
Crizotinib
Ceritinib
Brigatinib
Lorlatinib
Strengths:
Strong CNS penetration
Better survival outcomes
Market segment:
High-value oncology precision medicine
Pricing:
Premium targeted therapy market
15. Intellectual Property (IP)
Originator: Chugai / Roche
Patent protection:
Composition of matter (key patents still active in some regions)
Formulation + use patents
Biosimilar:
Not applicable (small molecule, but generic entry restricted by patents in some markets)
16. Environmental & EHS Knowledge
High-potency API handling required
Cytotoxic waste classification
Organic solvent recovery systems required
Worker safety:
PPE mandatory (oncology API exposure risk)
Closed-system manufacturing recommended
17. Export Documentation Knowledge
Required documents:
DMF (Drug Master File)
COA (API & finished product)
GMP certificate
Stability data (ICH)
Bioequivalence study reports
Polymorph characterization report
MSDS (cytotoxic handling classification)
Batch manufacturing alectinib API Wholesale Supplier in Brazil records
18. Business Development Knowledge
Target buyers:
Oncology hospitals
Cancer specialty distributors
Government oncology programs (limited)
Strategy:
Precision oncology positioning
Companion diagnostic partnerships
Key value proposition:
CNS metastasis effectiveness
First-line ALK NSCLC therapy standard
19. Advanced Technical Knowledge
ALK fusion drives oncogenesis via constitutive kinase activation
Alectinib inhibits ATP-binding site of ALK kinase domain
Active metabolite (M4) contributes significantly to efficacy
CNS penetration is critical differentiator
Resistance mechanisms:
ALK secondary mutations (e.g., G1202R)
20. AI & Digital Knowledge (Modern Pharma)
Applications:
AI-driven mutation resistance prediction (ALK variants)
Radiology AI for CNS metastasis response tracking
Pharmacokinetic modeling for dose optimization
Real-world evidence (RWE) oncology analytics
Digital companion diagnostics integration
21. Sales Team Product Knowledge Checklist
Sales must know:
ALK-positive NSCLC indication only
Requires genetic testing (ALK fusion)
Twice daily dosing with food
Strong brain metastasis efficacy
Liver toxicity monitoring required
Not interchangeable with other TKIs
High-value precision oncology therapy
22. Most Important Technical Documents
DMF / CMC Module 3
Stability studies (ICH Q1A/Q1B)
Polymorph characterization report (XRPD)
Bioequivalence studies (generic)
Impurity profile report
Clinical efficacy data (ALK trials)
Drug–diagnostic co-development data
Manufacturing validation batch records
23. Ultimate Pharma Product Mastery Summary
Alectinib is:
A next-generation ALK tyrosine kinase inhibitor
Designed for precision oncology in ALK-positive NSCLC
Highly effective in brain metastases due to CNS penetration
A high-value, targeted cancer therapy with biomarker dependency
???? Strategic importance:
Core drug in precision oncology portfolios
High-margin specialty oncology product
Strong demand in biomarker-driven cancer treatment
Central to ALK-positive NSCLC standard of care